Antibodies

15 June 2010

Trubion Provides Update on Clinical Development in RA

11 June 2010

Human Genome Sciences Announces Submission of Biologics License Application to FDA for BENLYSTA (belimumab)

10 June 2010

ARCALYST(R) (rilonacept) Meets Primary and All Secondary Endpoints in Phase 3 Trial of Prevention of Gout Flares in Patients Initiating Allopurinol Therapy

10 June 2010

HUMAN GENOME SCIENCES ANNOUNCES RESULTS OF RANDOMIZED PHASE 2 TRIAL OF MAPATUMUMAB IN MULTIPLE MYELOMA

9 June 2010

Immunomedics Presents New Antibody for Pretargeting Epithelial Cancers at Medical Conference

8 June 2010

New licence extension for RoACTEMRA in Europe

8 June 2010

Sanofi Pasteur Partners With Vivalis For The Discovery of Human Monoclonal Antibodies Against Infectious Diseases

8 June 2010

Immunomedics Reports First Clinical Experience With New Generation of Bispecific Antibody

7 June 2010

Investigational Compound Ipilimumab Demonstrates Improved Overall Survival in Phase 3 Trial of Previously-Treated Patients with Metastatic Melanoma

7 June 2010

Pooled Results of Early Endpoints from Phase 3 Trials of Genasense in Advanced Melanoma Presented at ASCO

7 June 2010

Phase III Study Showed Avastin-Based Regimen Helped Women with Advanced Ovarian Cancer Live Longer Without Their Disease Worsening

7 June 2010

Regulatory update – Benlysta (belimumab)

7 June 2010

Genmab Presents Data from a Pivotal Trial of Zalutumumab Versus Best Supportive Care in Patients with Refractory Head and Neck Cancer

7 June 2010

Progenics Phase 1 PSMA ADC Study Presented in New “Trials in Progress” Poster Session at ASCO Annual Meeting

7 June 2010

ImmunoGen, Inc. Announces Encouraging IMGN388 Clinical Data Reported at ASCO

7 June 2010

Celldex Therapeutics Presents New Clinical Data from Phase 2 Study of CDX-011 in Metastatic Melanoma at 46th Annual ASCO Meeting

7 June 2010

Micromet Presents Interim Update on Phase 1 Study of MT110 in Patients with Advanced Solid Tumors

7 June 2010

Immunomedics Reports Updated Results of Targeted Therapy for Advanced Pancreatic Cancer

6 June 2010

Alder Biopharmaceuticals’ ALD518 Antibody Therapeutic Reduces Disease Symptoms, Anemia in Phase 2a Clinical Trial in Non-Small Cell Lung Cancer Patients

5 June 2010

ImmunoGen, Inc. Announces Presentation of Clinical Data for Trastuzumab-DM1 at ASCO Annual Meeting

5 June 2010

Interim Positive Results From Phase 2b Brain Cancer Study With Rindopepimut (PF-04948568 or CDX-110) Presented at 46th Annual ASCO Meeting

5 June 2010

AVEO Pharmaceuticals Initiates Phase 2 Clinical Trial Evaluating SCH 900105 (AV-299) in Non-Small Cell Lung Cancer

5 June 2010

Denosumab Demonstrated Superiority Over Zometa(R) in Delay of Complications Due to Bone Metastases in Advanced Prostate Cancer

5 June 2010

New AMG 479 Phase 2 Data Show Antitumor Activity in Patients With Metastatic Pancreatic Cancer

5 June 2010

New Analyses of Denosumab Pivotal Phase 3 Trials Reinforce Potential Advantages Over Standard of Care

5 June 2010

Celldex Therapeutics Presents Positive Results from Phase 1/2 Advanced Breast Cancer Study with CDX-011 at 46th Annual ASCO Meeting

4 June 2010

Roche presents early data on the next generation of therapeutic antibodies and other targeted therapies at ASCO

2 June 2010

Ablexis Secures $12 Million in Series A Funding to Engineer and Commercialize Next-Generation Platforms for Antibody Drug Discovery

2 June 2010

FDA Advisory Committee Reviews MedImmune’s Motavizumab

1 June 2010

FDA Approves Amgen’s Prolia(TM) (Denosumab) for Treatment of Postmenopausal Women With Osteoporosis at High Risk for Fracture

News Channels

Newsletter

La Merie Biologics

La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.

Newsletter La Merie Biologics

Newsletter

New Product Alert

La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.

Newsletter new product alert

Featured reports

Pembrolizumab (Keytruda) Biosimilar Antibody Pipeline Review

CD40 Agonists & CD40/L Antagonists Pipeline Review

Ranibizumab (Lucentis) Biosimilars Pipeline Review

Competitor Analysis: Complement C5 Inhibitors & C5 Receptor Antagonists

Her3-Targeted Immunotherapy Pipeline Review

Mesothelin-Targeted Immunotherapy Pipeline Review

RNA-Targeted Novel Drug Modalities Based on RNA Editing, Epitranscriptomics, Direct RNA Targeting, Splicing Modulation, Translation Regulation, lncRNA & regRNA Targeting & More: a landscape analysis of technologies, targets, business and financing from an industry perspective

Report Package: TCR-Based Antibody and T-Cell Immunotherapy

B7-H3-Targeted Immunotherapy Candidates Pipeline Review

Blockbuster Biologics 2018: Sales of Recombinant Therapeutic Antibodies & Proteins